Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants

Inclusion Criteria: * Infants in stable health * Male or female 6 to 8 weeks of age * Signed informed consent by the infant's parent(s) or legally acceptable representative(s) Exclusion Criteria: * Known or suspected poliomyelitis * Known or suspected febrile(symptom of a fever), or chronic illnesses * Fever ≥ 38.0℃/100.4℉ within 3 days prior to study registration or intake of drug preventing fever * Known or suspected immune disorders (abnormal activity in protective system in human body) or received immunosuppressive therapy (treatment for weaken protective system in human body) * Previous use of blood or blood-derived products * Previous use of polio vaccines * Seizures (temporary abnormalities in muscle tone or movements due to abnormal activity in the brain) * Bleeding disorders * Household contact or intimate exposure with a confirmed case of polio * Any history of allergy (hypersensitivity) to the components of the polio vaccine * Participation in another interventional clinical trial simultaneously or within 30 days